LATE-BREAKING DATA FROM WSC2023: TOP-LEVEL RESULTS FROM ANNEXa-I TO INFORM CHOICE OF REVERSAL STRATEGY IN DOAC-ASSOCIATED ICH

Oct 10, 2023 | Antithrombotics

2) Our expert author is #ANNEXa_I investigator Ashkan Shoamanesh MD @Ash_Shoamanesh, #Stroke #Neurologist @HamHealthSci, Assoc Prof @McMasterU, & Director of Hemorrhagic Stroke Research Program & Scientist @PHRIresearch #FOAMed #FOAMcc #neurotwitter...

SUPPORTING HEMOSTASIS IN ANTI-FXa-ASSOCIATED INTRACRANIAL HEMORRHAGE: UPDATE FROM WSC2023

Oct 9, 2023 | Antithrombotics

2) Your faithful correspondent and faculty is #emergencymedicine specialist and #thrombosis researcher Charles Pollack MD @md_pollack from @UMMCnews. You can earn 0.5hr CE/#CME just from following this 🧵! Happy #WSC23023 eve! pic.twitter.com/o9nP9K5GG4—...

Live Tweetorial From ADA23 On Advances In Management Of Hyperlipidemia

Jun 24, 2023 | LIPIDS

1b) Patients with #diabetes #PWDs are of course at substantially increased risk of #CV disease, often in association with hyperlipidemia #HL. Therefore it's no surprise that a 🌶️topic at #ADA23 would be management of #HL and #CV disease prevention!#FOAMed...

HCM Prevalence, Pathophysiology, and Natural Course with and without Adequate Medical Treatment

Dec 21, 2022 | HCM

2a) This program is intended for #healthcare providers and is supported by an educational grant from Bristol-Myers Squibb. Statement of accreditation and faculty disclosures at https://t.co/gvXca4GHMU. FOLLOW US for the most timely expert education in #cardiometabolic...

Evaluating Post-Intervention Treatment Options for PAD

Jun 28, 2022 | PAD

2) The @cardiomet_ce program is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company, Bristol Myers Squibb & its Alliance partner Pfizer Inc, Chiesi, & Esperion. This program is intended for...